Pharmacotherapy of Obesity: Limits and Perspectives

American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions
Pamela Rosa-Gonçalves, David Majerowicz

Abstract

Obesity is a severe worldwide epidemic. Obesity comorbidities, such as type 2 diabetes mellitus, hypertension, and atherosclerosis, are costly for patients and governments. The treatment of obesity involves several facets, including lifestyle changes, bariatric surgery, and pharmacotherapy. As changes in lifestyle require considerable patient commitment that is sometimes unachievable, and surgery is expensive and invasive, pharmacotherapy is the primary option for most patients. This review describes the pharmacotherapy currently available in the USA, Europe, and Brazil, focusing on its limitations. We then analyze the results from clinical trials of new drug candidates. Most drugs cause weight loss of < 4 kg compared with controls, and severe adverse effects have caused a number of drugs to be withdrawn from the market in several countries. Drugs under development have not shown more significant weight loss or reduced adverse effects. We conclude that a significant portion of obese patients have few treatment options because of the adverse effects and minimal weight loss associated with current pharmacotherapy. However, drugs currently under development appear unable to change this scenario in the near future. Thus, it is esse...Continue Reading

References

Jun 1, 2000·Obesity Research·I L Mertens, L F Van Gaal
Feb 13, 2002·Journal of Human Hypertension·F G McMahonUNKNOWN Sibutramine in Hypertensives Clinical Study Group
Apr 18, 2002·European Journal of Clinical Nutrition·H H DitschuneitM Flechtner-Mors
May 15, 2002·European Journal of Pharmacology·Anne Ballinger, Steven R Peikin
Jun 8, 2002·Current Topics in Medicinal Chemistry·Wesley K KroezeBryan L Roth
Mar 28, 2003·The Annals of Pharmacotherapy·Ronald S MacWalterKatherine M Armstrong
Sep 17, 2003·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·R PadwalD C W Lau
Feb 6, 2004·Pharmacology & Therapeutics·David E Nichols
Feb 11, 2004·International Journal of Obesity and Related Metabolic Disorders : Journal of the International Association for the Study of Obesity·J K KaukuaA M Rissanen
Feb 19, 2004·Obesity Reviews : an Official Journal of the International Association for the Study of Obesity·S O'MearaG ter Riet
May 11, 2004·Nature Medicine·Mikhail G KoloninWadih Arap
Sep 6, 2006·International Journal of Obesity : Journal of the International Association for the Study of Obesity·P KopelmanP Valensi
Dec 7, 2006·Movement Disorders : Official Journal of the Movement Disorder Society·Robert A HauserVictor L Konyago
Jun 2, 2007·Pharmacological Reviews·George A Bray, Frank L Greenway
Nov 17, 2007·BMJ : British Medical Journal·Diana RuckerDavid C W Lau
Feb 7, 2008·The Journal of Pharmacology and Experimental Therapeutics·William J ThomsenDominic Behan
Mar 26, 2008·Archives of Internal Medicine·Karl HorvathAndrea Siebenhofer
May 27, 2008·Hormone and Metabolic Research = Hormon- Und Stoffwechselforschung = Hormones Et Métabolisme·Y YamadaK Kato
Nov 11, 2008·Obesity·Frank L GreenwayMichael A Cowley
Dec 2, 2008·Molecular and Cellular Endocrinology·David Russell-Jones
Dec 19, 2008·American Journal of Therapeutics·Richard B Rothman, Michael H Baumann
Feb 18, 2009·British Journal of Clinical Pharmacology·Andrew BrysonChristopher Dunk
Mar 5, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Anne Marie D AxelHenrik H Hansen
Apr 3, 2010·Strategies in Trauma and Limb Reconstruction·Shelain PatelElliot D Sorene
May 19, 2010·International Journal of Obesity : Journal of the International Association for the Study of Obesity·A SjödinA Astrup
Jul 22, 2010·The New England Journal of Medicine·Steven R SmithUNKNOWN Behavioral Modification and Lorcaserin for Overweight and Obesity Management (BLOOM) Study Group
Sep 8, 2010·The New England Journal of Medicine·W Philip T JamesUNKNOWN SCOUT Investigators
Mar 2, 2011·Progress in Lipid Research·Jessica E StewartRussell S J Keast
Jun 30, 2011·The Journal of Pharmacology and Experimental Therapeutics·Diane M IgnarJonathan D Hommel
Jul 29, 2011·The Journal of Clinical Endocrinology and Metabolism·Meredith C FidlerUNKNOWN BLOSSOM Clinical Trial Group
Sep 6, 2011·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Elsmarieke van de GiessenJan Booij

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.